173 related articles for article (PubMed ID: 15501236)
1. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2.
Hall H; Hubbell JA
Microvasc Res; 2004 Nov; 68(3):169-78. PubMed ID: 15501236
[TBL] [Abstract][Full Text] [Related]
2. Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo.
Hall H; Djonov V; Ehrbar M; Hoechli M; Hubbell JA
Angiogenesis; 2004; 7(3):213-23. PubMed ID: 15609076
[TBL] [Abstract][Full Text] [Related]
3. Mechanical properties, proteolytic degradability and biological modifications affect angiogenic process extension into native and modified fibrin matrices in vitro.
Urech L; Bittermann AG; Hubbell JA; Hall H
Biomaterials; 2005 Apr; 26(12):1369-79. PubMed ID: 15482824
[TBL] [Abstract][Full Text] [Related]
4. The induction of cell alignment by covalently immobilized gradients of the 6th Ig-like domain of cell adhesion molecule L1 in 3D-fibrin matrices.
Lühmann T; Hänseler P; Grant B; Hall H
Biomaterials; 2009 Sep; 30(27):4503-12. PubMed ID: 19523683
[TBL] [Abstract][Full Text] [Related]
5. Neurite extension and in vitro myelination within three-dimensional modified fibrin matrices.
Pittier R; Sauthier F; Hubbell JA; Hall H
J Neurobiol; 2005 Apr; 63(1):1-14. PubMed ID: 15616962
[TBL] [Abstract][Full Text] [Related]
6. Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro.
Hall H; Baechi T; Hubbell JA
Microvasc Res; 2001 Nov; 62(3):315-26. PubMed ID: 11678634
[TBL] [Abstract][Full Text] [Related]
7. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
[TBL] [Abstract][Full Text] [Related]
8. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
[TBL] [Abstract][Full Text] [Related]
9. Activation of cell-survival transcription factor NFkappaB in L1Ig6-stimulated endothelial cells.
Reidy M; Zihlmann P; Hubbell JA; Hall H
J Biomed Mater Res A; 2006 Jun; 77(3):542-50. PubMed ID: 16493660
[TBL] [Abstract][Full Text] [Related]
10. The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165.
Traub S; Morgner J; Martino MM; Höning S; Swartz MA; Wickström SA; Hubbell JA; Eming SA
Biomaterials; 2013 Aug; 34(24):5958-68. PubMed ID: 23683723
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.
Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L
Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514
[TBL] [Abstract][Full Text] [Related]
12. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
Reynolds AR; Reynolds LE; Nagel TE; Lively JC; Robinson SD; Hicklin DJ; Bodary SC; Hodivala-Dilke KM
Cancer Res; 2004 Dec; 64(23):8643-50. PubMed ID: 15574772
[TBL] [Abstract][Full Text] [Related]
13. FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin.
Nam JO; Son HN; Jun E; Cha K; Lee BH; Park RW; Kim IS
Mol Cancer Res; 2012 Aug; 10(8):1010-20. PubMed ID: 22710795
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha.
Stannard AK; Khurana R; Evans IM; Sofra V; Holmes DI; Zachary I
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):494-502. PubMed ID: 17170373
[TBL] [Abstract][Full Text] [Related]
15. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.
Fujiwara M; Muragaki Y; Ooshima A
Arch Dermatol Res; 2005 Oct; 297(4):161-9. PubMed ID: 16184401
[TBL] [Abstract][Full Text] [Related]
17. DICAM, a novel dual immunoglobulin domain containing cell adhesion molecule interacts with alphavbeta3 integrin.
Jung YK; Jin JS; Jeong JH; Kim HN; Park NR; Choi JY
J Cell Physiol; 2008 Sep; 216(3):603-14. PubMed ID: 18366072
[TBL] [Abstract][Full Text] [Related]
18. Endothelial cell response to lactate: implication of PAR modification of VEGF.
Kumar VB; Viji RI; Kiran MS; Sudhakaran PR
J Cell Physiol; 2007 May; 211(2):477-85. PubMed ID: 17167776
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase D1 regulates VEGF-A-induced alphavbeta3 integrin trafficking and endothelial cell migration.
di Blasio L; Droetto S; Norman J; Bussolino F; Primo L
Traffic; 2010 Aug; 11(8):1107-18. PubMed ID: 20477989
[TBL] [Abstract][Full Text] [Related]
20. Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2.
Zisch AH; Zeisberger SM; Ehrbar M; Djonov V; Weber CC; Ziemiecki A; Pasquale EB; Hubbell JA
Biomaterials; 2004 Jul; 25(16):3245-57. PubMed ID: 14980419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
